Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Andrew P Nicholls"'
Publikováno v:
Journal of Lipid Research, Vol 58, Iss 7, Pp 1306-1314 (2017)
Drug-induced phospholipidosis (DIPL) is characterized by an increase in the phospholipid content of the cell and the accumulation of drugs and lipids inside the lysosomes of affected tissues, including in the liver. Although of uncertain pathological
Externí odkaz:
https://doaj.org/article/8e757ee33bf04f40bdcc92d6d6d4ea82
Autor:
Emmanuelle Lecommandeur, Maria Begoña Cachón-González, Susannah Boddie, Ben D. McNally, Andrew W. Nicholls, Timothy M. Cox, Julian L. Griffin
Publikováno v:
Metabolites, Vol 11, Iss 1, p 18 (2020)
Sandhoff disease (SD) is a lysosomal disease caused by mutations in the gene coding for the β subunit of β-hexosaminidase, leading to deficiency in the enzymes β-hexosaminidase (HEX) A and B. SD is characterised by an accumulation of gangliosides
Externí odkaz:
https://doaj.org/article/2cfc0a9f51594020903d5a1919d93254
Autor:
Zsuzsanna Ament, James A. West, Elizabeth Stanley, Xuefei Li, Tom Ashmore, Lee D. Roberts, Jayne Wright, Andrew W. Nicholls, Julian L. Griffin
Publikováno v:
Data in Brief, Vol 8, Iss , Pp 196-202 (2016)
This article contains mass spectrometry (MS) data investigating small molecule changes as an effect of a triple peroxisome proliferator-activated receptor (PPAR-pan) agonist GW625019 in the liver as described in the manuscript (Ament et al., 2016) [1
Externí odkaz:
https://doaj.org/article/7f227b95d5d14a85aab124682e91c7b2
Publikováno v:
Toxins, Vol 3, Iss 6, Pp 504-519 (2011)
Overt response to a single 6.25 mg dose of ochratoxin A (OTA) by oral gavage to 15 months male rats was progressive loss of weight during the following four days. Lost weight was restored within one month and animals had a normal life-span without OT
Externí odkaz:
https://doaj.org/article/d5279fa28de84d53aca5ae6dfa71d788
Autor:
Rico Rueedi, Mirko Ledda, Andrew W Nicholls, Reza M Salek, Pedro Marques-Vidal, Edgard Morya, Koichi Sameshima, Ivan Montoliu, Laeticia Da Silva, Sebastiano Collino, François-Pierre Martin, Serge Rezzi, Christoph Steinbeck, Dawn M Waterworth, Gérard Waeber, Peter Vollenweider, Jacques S Beckmann, Johannes Le Coutre, Vincent Mooser, Sven Bergmann, Ulrich K Genick, Zoltán Kutalik
Publikováno v:
PLoS Genetics, Vol 10, Iss 2, p e1004132 (2014)
Metabolic traits are molecular phenotypes that can drive clinical phenotypes and may predict disease progression. Here, we report results from a metabolome- and genome-wide association study on (1)H-NMR urine metabolic profiles. The study was conduct
Externí odkaz:
https://doaj.org/article/41b8c1c4de3d4ac58249d128261afc41
Autor:
Antonella Napolitano, Sam Miller, Andrew W Nicholls, David Baker, Stephanie Van Horn, Elizabeth Thomas, Deepak Rajpal, Aaron Spivak, James R Brown, Derek J Nunez
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e100778 (2014)
UnlabelledMetformin, a biguanide derivate, has pleiotropic effects beyond glucose reduction, including improvement of lipid profiles and lowering microvascular and macrovascular complications associated with type 2 diabetes mellitus (T2DM). These eff
Externí odkaz:
https://doaj.org/article/0210c4a3a2ff4b068af2ccf58d9a2e0f
Autor:
Andrew P Nicholls, Andreas Mahler, Pradeep J. Nathan, Conn M Harrington, Rebecca L. Boardley, Paul Maruff, Alienor Berges, Joseph P. Horrigan, Richard Grove, Martin T. Lowy, Isabel Jm Beresford
Publikováno v:
Current Alzheimer Research. 11:47-58
Introduction: Histaminergic H 3 receptors may play a role in modulating cholinergic and monoaminergic neurotransmission. This Phase II study evaluated the efficacy and safety of GSK239512, a highly potent, brain penetrant H 3 receptor antagonist as m
Autor:
Richard A, Grove, Conn M, Harrington, Andreas, Mahler, Isabel, Beresford, Paul, Maruff, Martin T, Lowy, Andrew P, Nicholls, Rebecca L, Boardley, Alienor C, Berges, Pradeep J, Nathan, Joseph P, Horrigan
Publikováno v:
Current Alzheimer research. 11(1)
Histaminergic H3 receptors may play a role in modulating cholinergic and monoaminergic neurotransmission. This Phase II study evaluated the efficacy and safety of GSK239512, a highly potent, brain penetrant H3 receptor antagonist as monotherapy treat
Conference
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rubin, Aaron
Publikováno v:
Physician & Sportsmedicine; Apr98, Vol. 26 Issue 4, p22, 2p